Selecta Biosciences, Inc.
SELB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 30.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | – | 34.7% | 19.2% |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 0% | – | 14.6% | -8.1% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -199% | – | 31.9% | -30.2% |
| EPS Diluted | -0.5 | -1.42 | 0.24 | -0.22 |
| % Growth | 64.8% | -691.7% | 209.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |